Eli Lilly stock slips as Foundayo filing remains in focus

Eli Lilly stock traded at 1,304.90 euros on Lang & Schwarz at 16:30 CET on Thursday, November 12, 2026, 1.75% above the Xetra close of Wednesday, November 11, at 1,282.40 euros. The quote was 1.11% below the 1,319.50 euros recorded in the latest relevant report at 14:12 CET.

What has changed since the last report

The company has not announced a new regulatory decision since the earlier report, but the market is continuing to assess Lilly's latest clinical update. In a news release dated November 9, Eli Lilly said its oral GLP-1 medicine Foundayo, also known as orforglipron, reduced obstructive sleep-apnea severity in the Phase 3 ATTAIN-OSA program.

After 52 weeks, the apnea-hypopnea index fell by 43.8% among participants who did not use positive airway pressure therapy and by 27.5% among those who used it. In the first group, 31.5% of participants reached remission or mild disease under the trial criteria.

FDA filing remains the next catalyst

Lilly plans to submit Foundayo to the U.S. Food and Drug Administration for moderate-to-severe obstructive sleep apnea in adults with obesity or overweight by the end of 2026. The company said the trial also improved sleep-apnea-specific hypoxic burden, body weight, inflammation and systolic blood pressure.

For investors, the planned filing is the next defined step, while approval remains subject to regulatory review. The results could broaden Foundayo's role beyond weight management, although the release also reported gastrointestinal adverse events and higher discontinuation rates than placebo in both study groups.

Broader trading conditions can be followed in the current S&P 500 market reports.

More news and analyses on Eli Lilly and Company stock.